Albert Einstein College of Medicine, Yeshiva University: Open Journal Systems
Not a member yet
220 research outputs found
Sort by
Futile Care for the Terminally Ill: It May Be Legal But Is It Ethical or Morally Justifiable?
Get PDF
What's Ahead for Med Ed?
Get PDFIn response to biomedical advances and changes in the practice environment, medical education is always in the process of change. This paper deals primarily with educational changes involving the integration of the disciplines of genomics, prevention and population health, global health and integrative medicine into the curriculum. External and internal forces that tend to impede development of professional and humanistic values are also discussed along with the call to action for developing strategies that mitigate these forces.
The Department of Medicine at the Albert Einstein College of Medicine, Final Thoughts
Get PDFThe medicine we knew at the school’s beginning in 1955 was almost unrecognizable at the end of the twentieth century. The science, the knowledge base, the organization, and the funding of health care had all undergone dramatic changes. Fifty years ago, we thought we might be able to conquer infectious diseases. Now we are facing rampant ‘new’ diseases such as Human Immunodeficiency Virus (HIV) and Severe AcuteRespiratory Syndrome (SARS), and are witnessing the development of resistance to antibiotics by many microorganisms, including the previously highly sensitive pneumococcus. Fifty years ago, cardiac surgery was still in its youth, and mitral commissurotomies were highpoints of surgical endeavor. Now, rheumatic heart disease is very uncommon in the United States (although still common in parts of the third world). Fifty years ago, we had only primitive antihypertensive drugs, which were difficult for patients to tolerate. Now, antihypertensivedrugs are far more effective and better tolerated by patients. Fifty years ago, the structure and mechanism of replication of DNA had just been described by Watson and Crick. Now, we are using therapeutic agents manufactured by recombinant techniques, and are beginning to see clinical applications of gene transfer therapy
